



Media Contact: U.S. Stem Cell, Inc.  
13794 NW 4th Street, Suite 212  
Sunrise, Florida 33325  
Phone: 954.835.1500

*For Immediate Release*

**U.S. Stem Cell, Inc. (f/k/a/ Bioheart, Inc.) Receives FINRA Approval for Reverse Split and Name Change**

---

**Sunrise, FL – November 4, 2015 – U.S. STEM CELL, Inc.**, a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce that it has received approval, effective today, from the Financial Industry Regulatory Authority (“FINRA”) to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of its Common Stock. In connection with the Company’s reverse stock split, FINRA has assigned the Company a new stock symbol, BHRTD. The Company’s stock will be quoted as BHRTD through December 2, 2015, and thereafter, the trading symbol will be USRM (OTC Markets), reflecting the new name of the Company. The new CUSIP number is 90350U100. Additional information on the above transaction and name change can be found in our November 4, 2015 Form 8-K filing. Current stock certificates may be exchanged for new certificates by contacting the Company’s transfer agent, Continental Stock Transfer & Trust Company at:

**Continental Stock Transfer & Trust Company**  
**17 Battery Place, 8<sup>th</sup> Floor**  
**New York, NY 10004**  
**Tel. 1 (212) 508-4000**  
[www.continentalstock.com](http://www.continentalstock.com)

Company President and CEO, Mr. Mike Tomas, stated, “We are very pleased to have successfully completed the U.S. Stem Cell, Inc. name change and reverse split of our Common Stock. We firmly believe these actions will pave the way for our continuing and future business successes. We sincerely thank our shareholders for their patience during this transition. Our new U.S. Stem Cell website will be active shortly and we anticipate filing our 10-Q and reporting on our achievements for the quarter ending September 30, 2015 early next week.”

**About U.S. Stem Cell, Inc.**

US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (**US Stem Cell Training, Vetbiologics and US Stem Cell Clinic**) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

***Forward-Looking Statements:*** Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.